Ledipasvir (D-tartrate)

Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.

Product Specifications

CAS Number

[1502654-87-6]

Product Name Alternative

GS-5885 D-tartrate

UNSPSC

12352005

Target

HCV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Ledipasvir-D-tartrate.html

Purity

99.20

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(OC)N[C@H](C(N([C@H](C1=NC=C(C2=CC(C(F)(F)C3=C4C=CC(C5=CC=C6N=C([C@H]7N(C([C@@H](NC(OC)=O)C(C)C)=O)[C@]8([H])CC[C@@]7([H])C8)NC6=C5)=C3)=C4C=C2)N1)C9)CC%109CC%10)=O)C(C)C.O[C@@H]([C@@H](C(O)=O)O)C(O)=O

Molecular Formula

C53H60F2N8O12

Molecular Weight

1039.09

References & Citations

[1]Link JO, et al. Discovery of ledipasvir (GS-5885) : a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57 (5) :2033-46|[2]Hernandez D, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013 May;57 (1) :13-8.